Medpage Today on MSN9d
Defining Treatment Success in Chronic Spontaneous UrticariaWith unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...
Chronic spontaneous urticaria is an inflammatory skin disease that causes hives that last for at least six weeks. Derms ...
Flow Space on MSN17d
Kamala Harris' Medical Records Reveal She Has Urticaria-Here's What to Know About the Chronic ConditionEarlier this month, Vice President and presidential nominee Kamala Harris released a report with details about her health and ...
In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...
The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
1 While second-generation H1-antihistamines are standard therapy for both acute and chronic urticaria, some patients need additional treatment to find relief. A new study investigates whether ...
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback